Zhejiang Medicine released its 2026 interim report, with total operating revenue of 4.386 billion yuan and net profit attributable to the parent company of 606 million yuan, down 9.99% from the same period last year. Net cash inflow from operating activities was 452 million yuan, down 43.34% year on year. The company's asset-liability ratio was 18.48%, gross margin was 37.15%, ROE was 5.20%, and diluted earnings per share was 0.63 yuan. The number of shareholders was 55,600, and the top ten shareholders held 49.01% of the total share capital.
Zhejiang Medicine Co LtdNet profit fell 9.99% year on year and operating cash flow dropped 43.34%.
